Format

Send to

Choose Destination
J Clin Invest. 1991 Apr;87(4):1467-9.

Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.

Author information

1
Division of Basic and Clinical Immunology, University of California, Irvine 92717.

Abstract

Itraconazole is a recently developed triazole antifungal agent that inhibits cell membrane sterol biosynthesis. Itraconazole, in a dose-dependent manner, enhanced intracellular accumulation of daunorubicin and reversed the drug resistance in murine leukemia P388/ADR cells. In addition, itraconazole corrected the altered plasma membrane potentials of P388/ADR cells. The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections. Therefore, itraconazole is a potential candidate for in vivo use to reverse multidrug resistance in cancer with added benefit of its antifungal property.

PMID:
1849151
PMCID:
PMC295200
DOI:
10.1172/JCI115154
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center